Lineage Cell Therapeutics Inc (LCTX) — Cash Flow-to-Debt Ratio
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of $-3.62 Million could theoretically repay 0% of its total liabilities ($68.84 Million) in one year. See LCTX free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lineage Cell Therapeutics Inc Cash Flow-to-Debt Ratio (1991–2024)
Historical debt coverage capacity for Lineage Cell Therapeutics Inc across 34 annual periods. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Lineage Cell Therapeutics Inc (1991–2024)
Year-by-year debt coverage analysis for Lineage Cell Therapeutics Inc. Check earnings quality score of Lineage Cell Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-23.09 Million | $36.21 Million | ▲ +12.9% |
| 2023 | -0.73x | $-28.57 Million | $39.00 Million | ▼ -3678.2% |
| 2022 | 0.02x | $1.06 Million | $51.73 Million | ▲ +107.3% |
| 2021 | -0.28x | $-23.56 Million | $83.65 Million | ▲ +81.7% |
| 2020 | -1.54x | $-19.75 Million | $12.82 Million | ▲ +31.4% |
| 2019 | -2.24x | $-31.95 Million | $14.23 Million | ▲ +31.6% |
| 2018 | -3.28x | $-30.88 Million | $9.41 Million | ▲ +3.5% |
| 2017 | -3.40x | $-30.52 Million | $8.98 Million | ▲ +3.1% |
| 2016 | -3.51x | $-42.33 Million | $12.06 Million | ▼ -43.5% |
| 2015 | -2.45x | $-44.54 Million | $18.21 Million | ▲ +23.3% |
| 2014 | -3.19x | $-38.85 Million | $12.18 Million | ▼ -67.2% |
| 2013 | -1.91x | $-29.51 Million | $15.47 Million | ▲ +47.1% |
| 2012 | -3.61x | $-19.68 Million | $5.45 Million | ▼ -16.0% |
| 2011 | -3.11x | $-13.59 Million | $4.37 Million | ▼ -54.7% |
| 2010 | -2.01x | $-7.73 Million | $3.85 Million | ▼ -12.6% |
| 2009 | -1.79x | $-4.26 Million | $2.39 Million | ▼ -499.0% |
| 2008 | -0.30x | $-1.60 Million | $5.38 Million | ▲ +22.6% |
| 2007 | -0.38x | $-1.24 Million | $3.22 Million | ▲ +23.3% |
| 2006 | -0.50x | $-1.26 Million | $2.52 Million | ▲ +23.5% |
| 2005 | -0.66x | $-1.41 Million | $2.16 Million | ▲ +49.8% |
| 2004 | -1.31x | $-1.54 Million | $1.18 Million | ▼ -599.1% |
| 2003 | -0.19x | $-654.14K | $3.50 Million | ▲ +76.6% |
| 2002 | -0.80x | $-2.13 Million | $2.67 Million | ▲ +49.3% |
| 2001 | -1.57x | $-3.21 Million | $2.04 Million | ▲ +88.3% |
| 2000 | -13.50x | $-4.86 Million | $359.75K | ▼ -82.9% |
| 1999 | -7.38x | $-4.39 Million | $595.51K | ▼ -40.6% |
| 1998 | -5.25x | $-2.10 Million | $400.00K | ▼ -626.9% |
| 1997 | -0.72x | $-1.30 Million | $1.80 Million | ▲ +93.1% |
| 1996 | -10.50x | $-2.10 Million | $200.00K | ▲ +0.0% |
| 1995 | -10.50x | $-2.10 Million | $200.00K | ▼ -110.0% |
| 1994 | -5.00x | $-2.00 Million | $400.00K | ▲ +68.8% |
| 1993 | -16.00x | $-1.60 Million | $100.00K | ▼ -23.1% |
| 1992 | -13.00x | $-1.30 Million | $100.00K | ▼ -333.3% |
| 1991 | -3.00x | $-600.00K | $200.00K | — |